Levi & Korsinsky Initiates Class Action Against REGENXBIO for Alleged Securities Fraud
On March 4, 2026, Levi & Korsinsky, LLP announced a class action lawsuit aimed at protecting the interests of investors in REGENXBIO Inc., a biotechnology company listed on NASDAQ under the ticker RGNX. This legal action was initiated in response to claims of securities fraud that allegedly affected shareholders between February 9, 2022, and January 27, 2026.
The lawsuit seeks to recover losses incurred by investors who were misled by the company's allegedly false claims regarding the development of RGX-111, a gene therapy designed to treat the rare genetic disorder known as Hurler syndrome. REGENXBIO had previously assured its investors of the product's promising trial outcomes, citing positive safety and biomarker data from ongoing Phase I/II studies. However, it has been alleged that these positive statements were coupled with the concealment of critical negative information about the efficacy and safety of RGX-111.
The situation escalated when, on January 28, 2026, REGENXBIO reported that the FDA had placed a clinical hold on RGX-111 due to the discovery of a CNS tumor in one trial participant. In the aftermath of this announcement, REGENXBIO's stock plummeted by 17.8%, a severe drop from $13.41 to $11.01 per share within a single day.
Potential class members are advised that if they experienced a loss during the specified timeframe, they have until April 14, 2026, to request court appointment as lead plaintiff. Notably, participation in the lawsuit does not require lead plaintiff designation, allowing affected investors to benefit from any potential compensation without bearing any fees or costs upfront.
Levi & Korsinsky has a long-standing reputation in the field of securities litigation, recovering hundreds of millions for wronged shareholders over its two-decade history. With a dedicated team exceeding 70 professionals, the firm specializes in complex securities cases and has consistently ranked among the top litigation firms in the U.S. for shareholder claims.
Affected investors can reach out to Joseph E. Levi or Ed Korsinsky at the Levi & Korsinsky office located at 33 Whitehall Street, 27th Floor, New York, NY 10004, or contact them via email at [email protected] or by phone at (212) 363-7500 for more details regarding the lawsuit and the process to join.
In conclusion, this lawsuit symbolizes a critical endeavor to hold REGENXBIO accountable for its alleged misconduct, aiming to restore confidence among investors and ensure they receive justice for their losses incurred during this turbulent period.
The lawsuit seeks to recover losses incurred by investors who were misled by the company's allegedly false claims regarding the development of RGX-111, a gene therapy designed to treat the rare genetic disorder known as Hurler syndrome. REGENXBIO had previously assured its investors of the product's promising trial outcomes, citing positive safety and biomarker data from ongoing Phase I/II studies. However, it has been alleged that these positive statements were coupled with the concealment of critical negative information about the efficacy and safety of RGX-111.
The situation escalated when, on January 28, 2026, REGENXBIO reported that the FDA had placed a clinical hold on RGX-111 due to the discovery of a CNS tumor in one trial participant. In the aftermath of this announcement, REGENXBIO's stock plummeted by 17.8%, a severe drop from $13.41 to $11.01 per share within a single day.
Potential class members are advised that if they experienced a loss during the specified timeframe, they have until April 14, 2026, to request court appointment as lead plaintiff. Notably, participation in the lawsuit does not require lead plaintiff designation, allowing affected investors to benefit from any potential compensation without bearing any fees or costs upfront.
Levi & Korsinsky has a long-standing reputation in the field of securities litigation, recovering hundreds of millions for wronged shareholders over its two-decade history. With a dedicated team exceeding 70 professionals, the firm specializes in complex securities cases and has consistently ranked among the top litigation firms in the U.S. for shareholder claims.
Affected investors can reach out to Joseph E. Levi or Ed Korsinsky at the Levi & Korsinsky office located at 33 Whitehall Street, 27th Floor, New York, NY 10004, or contact them via email at [email protected] or by phone at (212) 363-7500 for more details regarding the lawsuit and the process to join.
In conclusion, this lawsuit symbolizes a critical endeavor to hold REGENXBIO accountable for its alleged misconduct, aiming to restore confidence among investors and ensure they receive justice for their losses incurred during this turbulent period.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.